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The immunostimulatory ability of synthetic oligonucleotides containing CpG motifs (CpG-ODN), agonists of Toll-like
receptor 9 (TLR9), can be harnessed to promote antitumor immunity by their application at the tumor site to stimulate
local activation of innate immunity; however, particularly in the lung, tumor-associated immunosuppression can
subvert such antitumor innate immune responses. To locally maintain continuous activation of innate subpopulations
while inhibiting immunosuppressive cells, we evaluated aerosol delivery CpG-ODN combined with Poly(I:C), a TLR3
agonist able to convert tumor-supporting macrophages to tumoricidal effectors, in the treatment of B16 melanoma
lung metastases in C57BL/6 mice. Aerosolization of CpG-ODN with Poly(I:C) into the bronchoalveolar space reduced the
presence of M2-associated arginase- and IL-10-secreting macrophages in tumor-bearing lungs and increased the
antitumor activity of aerosolized CpG-ODN alone against B16 lung metastases without apparent signs of toxicity or
injury of the bronchial-bronchiolar structures and alveolar walls. Moreover, CpG-ODN/Poly(I:C) aerosol combined with
dacarbazine, a therapeutic agent used in patients with inoperable metastatic melanoma able to exert
immunostimulatory effects, led to a signiﬁcant increase in antitumor activity as compared to treatments with
aerosolized CpG-ODN/Poly(I:C) or dacarbazine alone. This effect was related to an enhanced recruitment and cytotoxic
activity of tumor-inﬁltrating NK cells in the lung. Our results point to aerosol delivery as a convenient approach for
repeated applications of immunostimulants in patients with lung metastases to maintain a continuous local activation
of innate immune cells while suppressing polarization of tumor-inﬁltrating macrophages to an M2 phenotype.
Introduction
Toll-like receptors (TLRs) are well known for their ability to
activate innate immune cells recognizing pathogen- and danger-
associated molecular patterns. In light of their immunostimula-
tory activity, TLR agonists are included in the National Cancer
Institute list of immunotherapeutic agents with the highest
potential to cure cancer.1,2 With the exception of Imiquimod, a
synthetic TLR7 agonist topically applied to treat basal cell carci-
noma, most TLR agonists used in clinical trials have been admin-
istered systemically, since this route was reported to effectively
activate adaptive immunity.3 However, innate immune responses
triggered by TLR agonists include the activation of natural killer
(NK) cells, macrophages, neutrophils, monocytes and dendritic
cells, most of which must be activated locally, unlike cells of the
adaptive immune response which can reach the antigen wherever
they are activated.4 Local delivery of TLR agonists has been
explored for those cancers amenable to drug injection into the
tumor sites, and studies have shown the superior antitumor effect
of locoregional delivery of the TLR9 agonist CpG-ODN as com-
pared to systemic administration in experimental and clinical
cancers, such as ovarian and bladder cancers.1,2,5,6 For lung
tumors, repeated inhalation of TLR agonists represents a conve-
nient and practical approach to induce frequent replenishment of
innate immune effectors at the tumor site, avoiding toxic effects
of systemic treatment. Our studies of aerosol delivery of
CpG-ODN as a strategy for local administration of immunosti-
mulators7 showed that aerosolized CpG-ODN reached the bron-
choalveolar space, locally activated an immune response without
signs of toxicity, and was more efficacious than systemic adminis-
tration against lung metastases of N202.1A mammary carcinoma
cells. In contrast, aerosol delivery of CpG-ODN was minimally
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effective against metastases of B16 melanoma cells, which selec-
tively recruit CD68C macrophages with an M2 phenotype and
induce an immunosuppressive environment in the lung.7,8 Thus,
the tumor microenvironment is a critical factor for successful use
of these immunotherapeutics, and strategies to shift a tumor-sup-
porting milieu to a host-friendly one might lead to improved
antitumor activity of CpG-ODN.
Recent studies in mice showed that the TLR3 agonist Poly(I:
C) can convert lung tumor-associated macrophages (TAM) from
tumor supporters (M2) to those with tumoricidal properties
(M1).9,10 The conversion is related to Poly(I:C) signaling
through the TICAM-1/TRIF adaptor to induce expression of
M1-related genes in TAM, unlike other TLR agonists, which
activate a MyD88-dependent signaling pathway.9 Moreover,
TLR3 agonists can also trigger an innate immune response11,12
and have been shown to induce antitumor activity when used
alone or in combination with an anti-cancer vaccine.13-17 Thus,
aerosol-delivered TLR3 agonists might improve the CpG-ODN-
induced innate immune antitumor response even in the presence
of an immunosuppressive tumor microenvironment.
Here, we evaluated aerosol administration of CpG-ODN
combined with Poly(I:C) for its effectiveness in simultaneously
blocking TAM-induced immunosuppression and maintaining
continuous activation of innate immune cells in the treatment of
experimental B16 melanoma lung metastases. Aerosolization of
CpG-ODN/Poly(I:C) was also evaluated in combination with
dacarbazine, an alkylating agent used as a therapeutic standard in
patients with inoperable metastatic melanoma.
Results
CombinedPoly(I:C) and CpG-ODN aerosolization reduces
the number of arginase- and IL-10-secreting tumor-associated
macrophages
As previously observed for TLR9 agonist CpG-ODN,7 the
aerosolized TLR3 agonist Poly(I:C) reached the bronchoalveolar
space and recruited immune cells of C57BL/6 mice (5–10 mice
in the same aerosol box), as demonstrated by the significant
increase of F4/80CCD11c- macrophages and dendritic cells in
suspensions obtained after enzymatic digestion of lungs of Poly
(I:C)-treated mice compared to saline-treated mice (Fig. 1).
To assess the antitumor activity of the aerosolized CpG-
ODN/Poly(I:C) combination, we first tested whether this treat-
ment affects M2 macrophages, which are selectively recruited by
B16 melanoma cells in the lung.7,8 C57BL/6 mice injected i.v.
with 5 £ 105 B16 melanoma cells were treated with aerosolized
CpG-ODN/Poly(I:C) or aerosolized CpG-ODN alone twice
weekly starting 4 d after tumor cell injection. Immunohisto-
chemical analyses of lung sections obtained at the end of the
experiment revealed a significant reduction of arginase-positive
macrophage and CD163-positive macrophages,14 in the CpG-
ODN/Poly(I:C)-treated mice as compared to untreated mice
(Mean number § SEM of arginase-positive cells: 16.4 § 2.1 in
CpG-ODN/Poly(I:C)-treated vs. 24.7 § 2.2 in untreated,
pD0.015; mean number § SEM of CD163-positive cells: 1.5 §
0.7 in CpG-ODN/Poly(I:C)-treated vs. 7.4 § 0.45 in untreated,
p< 0.0001; evaluated on 10 fields/group), whereas the number
of these cells was only slightly reduced in lungs of mice treated
with CpG-ODN alone (Arginase-positive cells: 20.6 § 2.6;
CD163-positive cells: 3.8 § 0.5) (Fig. 2A). The reduction of
M2 macrophages was confirmed by double-immunofluorescence
analysis, which revealed the reduced presence of CD68C macro-
phages secreting IL-10 mostly in mice treated with the CpG-
ODN/Poly(I:C) combination (Fig. 2B). Consistent with our
previous results,7 CpG-ODN aerosol treatment alone failed to
modify the number of NK cells in lungs bearing the B16 tumor,
while the reduction of M2 macrophages induced by the CpG-
ODN/Poly(I:C) combination allowed locally delivered CpG-
ODN to expand NK cell numbers, as revealed by flow cytometric
analysis of CD45C tumor-infiltrating cells in lungs of mice
injected i.v. with B16 cells and treated with aerosolized CpG-
ODN alone or combined with Poly(I:C) (mean % DX5C/
CD3-/CD45C § SD: 22.8 § 1.5% in untreated; 23.9 § 2.5%
in CpG-ODN-treated; 25.5 § 1.6 in Poly(I:C)-treated; 32.7 §
2.1% in CpG-ODN/Poly(I:C)-treated; 4 mice/group; pD0.036
CpG-ODN/Poly(I:C) vs. CpG-ODN; p D 0.0094) (Fig. S1).
Together, the results indicate that the aerosolized CpG-ODN/
Poly(I:C)combination reduces the presence of macrophages
expressing M2-associated markers and allows the expansion of
tumor-infiltrating NK cells in B16 tumor-bearing lungs.
Combination of Poly(I:C) with CpG-ODN improves
the antitumor activity of aerosolized CpG-ODN against B16
lung metastases
The possible synergistic effect of the two TLR agonists con-
comitantly administered was investigated by comparing the anti-
tumor effect of this combination to that of treatment with each
agonist alone in mice bearing B16 tumors and treated twice
weekly for 3 weeks starting 4 d after tumor injection. A control
group of mice injected with tumor cells was left untreated. At the
end of the experiment, the number of lung colonies was signifi-
cantly lower in mice treated with aerosolized CpG-ODN/Poly(I:
C) than in mice treated with each aerosolized ligand alone (P <
0.001 CpG-ODN/Poly(I:C) vs. CpG-ODN; P < 0.05 CpG-
ODN/Poly(I:C) vs. Poly(I:C)) (Fig. 3A). No body weight loss
was observed in mice exposed to aerosolization with both TLR
agonists.
Since the combination of two potent TLR ligands into the air-
ways reaching lung parenchyma might lead to lung inflammation,
the effect of repeated aerosolized CpG-ODN/Poly(I:C) treatment
was evaluated in not bearing tumors mice. Histopathological
examination of hematoxylin and eosin-stained sections of lung tis-
sues showed the absence of injury of the bronchial-bronchiolar
structures and of the alveolar walls in all lungs of four mice treated
with TLR3 and TLR9 agonists. Focal areas of mononuclear and
granulocytic infiltrate of the interstitium and no overt signs of tox-
icity, such as weight loss, hunching, ruffled fur or difficulty breath-
ing were observed (Fig. 3B). Thus, the CpG-ODN/Poly(I:C)
combination increased the antitumor activity of aerosolized CpG-
ODN against B16 lung metastases without apparent evidence of
lung injury or other signs of toxicity.
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Dacarbazine increases the antitumor activity of aerosol
CpG-ODN/Poly(I:C) in mice bearing B16 lung metastases
The alkylating agent dacarbazine is a standard first-line treat-
ment in patients with metastatic melanoma. This chemothera-
peutic agent has recently been shown to enhance the expression
of NKG2D ligands on tumor cells, thus favoring NK cell cyto-
toxicity.15 Since antitumor activity of TLR agonists is, in part,
mediated by NK cells, we tested whether dacarbazine might
increase the antitumor activity of CpG-ODN/Poly(I:C) aerosol
treatment. Flow cytometry analysis revealed that in vitro treat-
ment of B16 melanoma cells with dacarbazine induced the upre-
gulation of RAE1 and MULT1 (Fig. 4A), while PCR showed
that treatment of B16 tumor-bearing mice for 3 weeks with
dacarbazine (80 mg/kg administered i.p., 5 days/week) induced
an increase of Rae1 and Mult1 mRNA in lungs (Fig. 4B), con-
firming the dacarbazine-induced up-modulation of NKG2D
ligands on B16 tumor cells. To assess the effect of dacarbazine
combined with CpG-ODN/Poly(I:C) aerosol on B16 lung
metastases, four groups of mice were injected i.v. with B16 mela-
noma cells and three groups were treated 4 d later with dacarba-
zin alone (80 mg/kg administered i.p., 5 days/wk) or with
CpG-ODN/Poly(I:C) aerosolization alone or with dacarbazin
combined with aerosol CpG-ODN/Poly(I:C); the fourth group
of mice was left untreated and used as control. Although the
number of lung metastases was significantly reduced at the end of
the experiment in mice receiving dacarbazine or aerosolized
CpG-ODN/Poly(I:C) as compared to untreated mice, the com-
bination of CpG-ODN/Poly(I:C) aerosol with dacarbazine
induced a significantly increased antitumor activity as compared
to Poly(I:C)/CpG-ODN aerosol or dacarbazine alone, resulting
in complete cure in three of eight mice at the end of the experi-
ment (Fig. 5). The combination of dacarbazine with aerosolized
CpG-ODN/Poly(I:C) to treat more advanced lung tumors, i.e.,
those for which treatment was delayed by 1 week, also signifi-
cantly increased the antitumor activity of dacarbazin (mean
number of lung metastases § SD: untreated mice 23.9 § 7.3;
Figure 1. Recruitment of innate immune cells in lungs of mice treated with aerosolized TLR3 agonist Poly(I:C). Percentage and representative dot plots of
macrophages, identiﬁed as CD11c-F4/80C cells among CD45C cells (A), and dendritic cells, identiﬁed as CD11cCF4/80- cells gated on CD11bC cells (B),
obtained by enzymatic digestion of lungs from mice (four mice/group) treated three times at 24-h intervals with aerosolized TLR3 agonist poly(I:C)
(15 mg) or saline. *p < 0.05.
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CpG-ODN/Poly(I:C)-treated mice 8.9 § 4.8; dacarbazine-
treated mice 7.9 § 3.8; dacarbazine plus aerosolized CpG-
ODN/Poly(I:C) 4.0 § 3.1; p D 0.018 dacarbazine plus CpG-
ODN/Poly(I:C) vs. dacarbazine alone). It should be noted that
the combination of the two aerosolized TLR agonists was still
effective even when the treatment started 1 week after tumor
infection (p D 0.0004 vs. untreated mice).
Dacarbazine increases NK cell recruitment and activity in
B16 metastases-bearing lungs of mice treated with aerosol
CpG-ODN/Poly(I:C)
NK cells are reported to be the major effectors required to coun-
teract the growth of B16 melanoma lung metastases,16-18 even if an
involvement of adaptive immune cells cannot be excluded. We
compared the leukocyte infiltration and the percentage and activa-
tion of NK effector cells in B16melanomametastases bearing lungs
treated with aerosol CpG-ODN/Poly(I:C) alone, dacarbazine alone
or dacarbazine combined with aerosol CpG-ODN/Poly(I:C) as
above. Flow cytometric analysis of enzymatically digested lung tis-
sue revealed no significant difference in the percentage of CD45C
cells in lung suspensions obtained from mice of the different
groups. A significant increase of the frequency of NK cells
(DX5CCD3¡) was induced by aerosol CpG-ODN/Poly(I:C) as
compared to untreated mice; a stronger increase in the percentage
ofNK cells was observed inmice treated with dacarbazine plus aero-
sol CpG-ODN/Poly(I:C) as compared to treatments with CpG-
ODN/Poly(I:C) or dacarbazine alone (Fig. 6A). Besides inducing
the highest percentage of NK cells in the tumor bearing lungs, the
combination of dacarbazine with aerosolized CpG-ODN/Poly(I:
C) also induced the highest expression of the cell surface activation
marker CD69 (Fig. 6B). Although not statistically significant, NK
cells obtained from lungs of mice treated with this combination
also showed increased NKG2D expression (Fig. 6C), the activating
receptor essential in NK-mediated elimination of tumor cells.19
Figure 2. Arginase- and IL-10-secreting macrophages in lungs of B16 tumor-bearing mice treated with CpG-ODN or CpG-ODN/Poly(I:C) aerosol. Immuno-
histochemical staining for arginase I-expressing and CD163-expressing (A) macrophages in formalin-ﬁxed, parafﬁn-embedded lung tissue collected after
i.v. injection of 5 £ 105 B16 melanoma cells from mice treated with aerosolized CpG-ODN alone or combined with Poly(I:C) or left untreated (3–4 mice/
group). CpG-ODN/Poly(I:C) was more effective than CpG-ODN alone in reducing the number of arginase I-positive and CD163-positive M2 macrophages
populating the interstitium as compared to untreated controls. Original magniﬁcation x400; Inset in upper right panel is a higher-magniﬁcation (x630)
showing the cell morphology of macrophages inﬁltrating the lungs of untreated mice. Histograms in the bottom show the mean number of arginase I-
expressing or CD163-expressing macrophages in lung tissue evaluated on 10 ﬁelds/group. *p < 0.05; ***p < 0.001.Representative immunoﬂuorescence
images of lung samples showing M2-polarized macrophages as CD68 (red)-positive cells also expressing IL-10 (green) (B). Original magniﬁcation x400.
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Parallel experiments were per-
formed to analyze whether the
increased percentage and maturation
of NK cells in mice treated with aero-
sol CpG-ODN/Poly(I:C) plus dacar-
bazine corresponded to increased
activity against B16 tumor cells. Four
groups of mice were injected i.v. with
B16 melanoma cells and treated as
above; at the end of treatments, cell
suspensions obtained by enzymatic
digestion of lung tissue were co-cul-
tured with B16 melanoma cells for
24 hr and cytotoxicity of NK cells
was evaluated by a degranulation
assay. While aerosol CpG-ODN/
Poly(I:C) or dacarbazine alone
induced an increase in the percentage
of degranulating NK cells, the highest
percentage of such cells was observed
in suspensions obtained from lungs
of mice treated with aerosol CpG-
ODN/Poly(I:C) plus dacarbazin
(increase in the percentage of degra-
nulating NK cells vs. untreated: 2.4-
fold in CpG-ODN/Poly(I:C) C
dacarbazine, 1.8-fold in CpG-ODN/
Poly(I:C) and 1.5-fold in dacarbazine
alone) (Fig. 6D). These data were
corroborated by results obtained by
evaluation of cytotoxic activity of
lung immune cells of mice untreated
or treated as above on CFSE-labeled
B16 target cells (Fig. 6E), that
revealed a significant increase in the
percentage of dead B16 cells after co-
culture with lung suspensions from
CpG-ODN/Poly(I:C) C dacarba-
zine-treated mice (p D 0.028). Alto-
gether these results indicate that
dacarbazine combined with aerosol
CpG-ODN/Poly(I:C) increases the
antitumor activity of the two ago-
nists, and that this effect was in part
related to the ability of dacarbazine
to enhance the cytotoxic activity of
NK cells induced by locally adminis-
tered TLR agonists.
Discussion
Inhalation of drug aerosols is a
promising pathway to combat lung
diseases and also represents an option
for treating asthma and chronic
Figure 3. Effects of aerosolized CpG-ODN/Poly(I:C) on the growth of B16 lung metastases and on lung
parenchyma of tumor-free mice. (A) Number of macroscopic lung metastases after i.v. injection of B16
melanoma cells in mice untreated (7 mice) or treated with CpG-ODN aerosol (12 mice), Poly(I:C) aerosol
(12 mice) orCpG-ODN/Poly(I:C) aerosol (14 mice)*p <0.05; ***p <0.001. (B) Histopathological evaluation
of hematoxylin and eosin-stained lung tissue sections from aerosolized CpG-ODN,Poly(I:C),or CpG-ODN/
Poly(I:C) mice and untreated mice. Note focal areas of mononuclear and granulocytic inﬁltrate (magniﬁ-
cation x400).
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obstructive pulmonary disease. Advantages to aerosol administra-
tion of medications to the lung include a high local concentration
by delivery directly to the airways, a reduced distribution to sys-
temic circulation and, for drugs that would otherwise require
subcutaneous or intravenous injection, pain- and needle-free
delivery. Several therapeutic agents have been explored for inhala-
tion delivery in malignancies, including chemotherapeutic
agents,20,21 cytokines,22,23 antisense oligonucleotides24 and
monoclonal antibodies,25 demonstrating the feasibility of aerosol
delivery, potential antitumor effects and reduced side-effects
compared to systemic treatment.
In the present study, we explored the aerosol administration of
TLR3 agonist Poly(I:C) combined with the TLR9 agonist CpG-
ODN to target tumor-infiltrating immune cells as a novel
approach to the treatment of lung metastases. Our results indi-
cated that aerosolization of the two TLR agonists into the bron-
choalveolar space did not induce evident signs of toxicity on
mice and/or signs of injury in the architecture and structure of
lung parenchyma. Because of the continuous contact of airway
lung epithelial cells with invading microbes, the pulmonary
microenvironment represents a unique milieu in which carcino-
genesis can proceed supported by an inflammatory context and
by the presence of a significant population of immunosuppressive
cells. TAMs are one of the major immunosuppressive cells affect-
ing the tumor microenvironment able to influence tumor pro-
gression and the success or failure of immunotherapy,26 and
emerging evidence reveals a significant correlation between high
TAM numbers and poor patient prognoses in lung cancer
patients.In advanced NSCLC patients treated (first-line) with an
EGFR-TKI, M2-polarized counts was associated with a marked
decrease in treatment response27 and correlated with lymph node
metastasis and poor prognosis.28,29 Moreover, several studies
have suggested a role for the expression of the immunosuppres-
sive cytokine IL-10 by TAMs in the progression and prognosis of
NSCLC.30,31 We found that the addition of Poly(I:C) to aerosol-
ized CpG-ODN resulted in increased antitumor activity in mice
bearing B16 lung metastases as compared to mice treated with
either aerosolized agonist alone. The enhanced antitumor effect
of the CpG-ODN/Poly(I:C) aerosol combination correlated
with a significant reduction in the number of macrophages pro-
ducing arginase and/or IL-10 and/or CD163 expressing macro-
phages, three different markers of the M2 phenotype, which are
selectively recruited by B16 melanoma cells in the lung and
responsible for the low efficacy of locally delivered CpG-ODN
alone.7
Besides blocking conversion of TAM to the M2 pheno-
type, Poly(I:C) treatment was recently shown to promote the
maturation of myeloid-derived suppressive cells (MDSC),
immature cells often elevated in tumor-bearing hosts, render-
ing them competent for NK cell activation. Indeed, incuba-
tion of Poly(I:C)-treated CD11bCGr1C MDSC cells with
NK cells induced the upregulation of CD69 expression on
the NK cell surface and increased their interferon-g produc-
tion.10 Our results indicated that the combination of Poly(I:
C) with aerosolized CpG-ODN significantly expanded the
frequency of DX5C cells in lung tumor infiltrates and
increased their cytotoxic activity against B16 tumor cells.
Thus, activation of NK cells might depend on a direct effect
of aerosolized CpG-ODN on NK cells induced by the block-
ing of suppressive macrophages, but also on an indirect effect
of Poly(I:C) on NK cells through the induction of NK cell-
activating molecules on MDSC present in the tumor
microenvironment.
Since a heightened immune response alone can rarely cure
patients, we also evaluated the combination of aerosolized
Figure 4. Up-modulation of NKG2D ligand expression on dacarbazine-
treated B16 melanoma cells. (A) MULT1 and RAE1 expression on the cell
surface of B16 melanoma cells analyzed by ﬂow cytometry after 24-h cul-
ture in complete medium alone (PBS) or supplemented with dacarbazine
(DTIC) at different concentrations. The mean ﬂuorescence intensity (MFI)
was normalized to the isotype control. One representative experiment of
2 conducted is shown. (B) Increase in Mult1 and Rae1 mRNA expression
in lungs of mice injected i.v. with B16 melanoma cells and untreated or
treated for 3 weeks with DTIC (80 mg/kg administered i.p. 5 days/week)
(3 mice/group). Data represent mean relative expression (normalized to
GAPDH) § SD from three independent real-time PCR analyses.
***p <0.001.
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CpG-ODN/Poly(I:C) with chemother-
apy. Until recently, chemotherapeutic
drugs have been studied only with
respect to their cytotoxic activity
against tumor cells, but accumulating
evidence indicates that at least some of
them have broader activities. Dacarba-
zine, for example, was recently shown
to trigger the expression of NKG2D
ligands on mouse tumor cells, thus
indirectly promoting NK cell cytotox-
icity.32 Moreover, Hervieu et al.15
demonstrated that coculture of differ-
ent human NK cells with dacarbazine-
treated human melanoma cell lines
was shown to sensitize the melanoma
cells to NK cell lysis, with the increase
in mortality of target cells prevented
by an anti-human NKG2D antibody.
Accordingly, our results indicated that
treatment with dacarbazine up-modu-
lated RAEI and MULTI expression in
B16 melanoma cells both in vitro and
in vivo, and that the combination of
dacarbazine and aerosol CpG-ODN/
Poly(I:C) induced a significant increase
in the frequency and degranulation
activity of DX5C cells, resulting in
improved antitumor activity. Note
that the induction of NKG2D ligand
expression has also been observed for other genotoxic agents,
such as 5-fluorouracil and cisplatin,33,34 raising the possibility
that these chemotherapeutic drugs might also increase the
antitumor activity of aerosol CpG-ODN/Poly(I:C).
In conclusion, our study identifies repeated aerosol delivery of
immunostimulants, such as TLR9 and TLR3 agonists, as a con-
venient and simple approach to locally maintain activation of
innate immune cells while inhibiting polarization of tumor-infil-
trating macrophages to the M2 phenotype, minimizing their pos-
sible systemic side-effects. This strategy might improve the
response to standard treatments with chemotherapeutic agents by
maintaining an immune microenvironment able to counteract
tumor growth.
Materials and Methods
Cell lines and reagents
B16 mouse melanoma cells were routinely maintained at
37C in a 5% CO2 atmosphere in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum and
2 mM glutamine. Purified, phosphorothioated TLR-9 agonist
ODN1826 (50-TCCATGACGTTCCTGACGTT-30) con-
taining CpG motifs was synthesized by TriLink Biotechnolo-
gies. Low-molecular weight polyinosinic-polycytidylic acid
(Poly(I:C)), a synthetic analog of double-stranded RNA
(dsRNA) and an agonist of TLR-3, was purchased from
Invivogen (tlrl-picw-250). Dacarbazine was provided by
Medac GmbH (AIC033645021).
Mice and experimental protocols
All experiments were carried out using 8- to 12-week-old
female C57BL/6 mice (Charles River) maintained in laminar-
flow rooms at constant temperature and humidity, with food and
water given ad libitum. Experiments were approved by the Ethics
Committee for Animal Experimentation of the Fondazione
IRCCS IstitutoNazionaledeiTumori of Milan according to insti-
tutional guidelines. Mice were injected intravenously (i.v.) with 5
£ 105 B16 melanoma cells and treated starting 4 or 7 d later
with aerosol at 72- to 96-hr intervals or with dacarbazine admin-
istered intraperitoneally (i.p.) at 70 mg/Kg, 5 days/week for 3 or
2 weeks, respectively. Mice were weighed twice weekly. Aerosol
administration was performed using a mouse whole-body expo-
sure system (EMMS) as described.7 Poly(I:C) (15 mg) or CpG-
ODN (1.5 mg) were dissolved in 5 mL saline and placed in the
nebulizer unit to treat up to 10 mice placed in the aerosol box;
mice were exposed to aerosol for 15 min, with the 5 mL volume
of liquid in the nebulizer nearly consumed in 10 min. At the end
of the experiments, all mice were euthanized and macroscopic
lung metastases were counted. All in vivo experiments were
repeated at least twice.
Figure 5. Antitumor activity of aerosol CpG-ODN/Poly(I:C) combined with dacarbazine (DTIC) on B16
experimental lung metastases. Number of macroscopic B16 melanoma lung metastases in mice
untreated (7 mice) or treated with aerosol CpG-ODN/Poly(I:C) (8 mice), DTIC (8 mice), or aerosol CpG-
ODN/Poly(I:C) plus DTIC (8 mice) starting 4 d after tumor injection (A), and in mice untreated (7 mice)
or treated with aerosol CpG-ODN/Poly(I:C) (8 mice), DTIC (7 mice), or aerosol CpG-ODN/Poly(I:C) plus
DTIC (16 mice) starting 1 week after tumor injection (B). *p<0.05; ** p < 0.01 ***p < 0.001.
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Histological, immunofluorescence and
immunohistochemical examination of lungs
Lung samples obtained from mice treated with aerosolized
CpG-ODN, Poly(I:C), or CpG-ODN/Poly(I:C) as described
above or untreated were fixed in 10% neutral buffered formalin,
embedded in paraffin, sectioned at 5 mm and stained with
hematoxylin and eosin for histological evaluation by light micros-
copy (Scan Scope Aperio, Nikon).
Immunofluorescence and immunohistochemical analyses were
performed to analyze macrophage infiltration on lung sections
collected from mice after i.v. injection of B16 cells (four mice/
group) untreated or treated with aerosolized CpG-ODN alone
or combined with Poly(I:C). For immunohistochemistry, tissue
samples were fixed in 10% buffered formalin and paraffin-
embedded, sectioned (4-mm thick), deparaffinized and rehy-
drated. Antigen unmasking was performed using pH 9 Tris/
EDTA buffer (Novocastra, RE7119) in a PT Link Dako unit at
98C for 30 min. Sections were then brought to room tempera-
ture and washed in PBS. After neutralization of endogenous per-
oxidase with 3% H2O2 and Fc blocking by a specific protein
(Novocastra, RE7157), samples were incubated with polyclonal
rabbit anti-mouse arginase antibody (1:200, Genetex Interna-
tional Corp., GTX109242) or polyclonal rabbit anti-mouse
CD163 antibody (1:100, Abcam AB199402) for 1 hr at room
temperature. Staining was revealed by a polymer detection kit
(Novocastra, RE7280-K) and AEC (3-amino-9-ethylcarbazole,
Dako, K3464) substrate-chromogen. Slides were counterstained
with Harris hematoxylin (Diapath, CO286). For immunofluo-
rescence analysis, polyclonal rabbit anti-mouse CD68 (1:100,
Abcam, AB125047) and rat anti-mouse IL-10 (1:200, Novus
Biologicals, Clone JES5-2A5) were used. Antigen unmasking was
performed using pH 6 citrate buffer (Novocastra, RE7113) in a
PT Link Dako unit at 98C for 30 min. After Fc blocking, pri-
mary antibody binding was revealed by Alexa 488-conjugated
goat anti-rat (Invitrogen Molecular Probes, A11006) and Alexa
568-conjugated goat anti-rabbit (Invitrogen Molecular Probes,
A11011) secondary antibodies. Rat isotype control (eBioscience
Rat IgG1 isotype control clone eBRG1) and an unrelated rabbit
antibody ((Invitrogen Rabbit isotype control catalog number
08-6199), used as controls to verify the specific reactivity of argi-
nase and IL-10 staining, did not reveal any staining. Slides were
counterstained with DAPI nucleic acid stain (Invitrogen Molecu-
lar Probes, D1306). All sections were analyzed under a Leica
DM2000 optical microscope (Leica Microsystems) and micro-
photographs were collected using a Leica DFC320 digital camera
(Leica).
Quantitative PCR analysis
Lung samples of mice bearing B16 melanoma cells treated
with dacarbazine for 3 weeks or untreated were cut into small
pieces and homogenized with QIAzolLysis Reagent (QIAGEN,
79306). Total RNA was isolated according to the manufacturer’s
instruction and reverse transcription was performed using Super-
Script III First-Strand (Invitrogen, 18080-044). Real-time PCR
was performed with Power SYBR Green PCR Master Mix
(Applied Biosystems, P/N 4385612) with a StepOne Real-Time
PCR System (Applied Biosystems), using the following primers:
RAE1 rev: 50-CCC TCC TCT GGC CTC TCC TT -30; RAE1
for: 50-CCC CAG TAT CAC CCA GCT TAC AT-30; MULT1
rev: 50-CAT CCA AGA GAG GTG GTG GT-30; MULT1 for:
50-AGC TCA TGT TGC ACT GGA AA-30. Expression of the
gene was normalized to GAPDH.
Figure 6. Recruitment and activation of NK cells in B16 metastases-bear-
ing lungs of mice treated with CpG-ODN/Poly(I:C) aerosol combined
with dacarbazine. Percentage and representative dot plots of NK cells,
evaluated as DX5C cells gated on FSClowSSClowCD45CCD3- cells (A),
and of CD69C (B) and NKG2DC (C) NK cells, gated on DX5C cells,
obtained by enzymatic digestion of B16 metastases-bearing lungs of
mice (4 mice/group) treated with aerosol CpG-ODN/Poly(I:C), DTIC, aero-
sol CpG-ODN/Poly(I:C) plus DTIC or left untreated. Percentage and repre-
sentative dot plots of degranulating NK cells, evaluated as CD107aC
cells gated on CD45CCD3-DX5C cells, after co-culture with B16 mela-
noma cells (D), and of CFSE-labeled B16 dead cells, evaluated as 7AADC
cells gated on CFSEC cells, after co-culture with cells obtained from lung
enzymatic digestion (E). *p < 0.05, ***p < 0.001.
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Multi-parameter flow cytometry
To evaluate leukocyte lung infiltrates, lungs from mice treated
with aerosolized poly(I:C) or saline or from mice injected with
tumor cells and treated for 2 weeks with aerosolized CpG-ODN
alone or combined with Poly(I:C) or with dacarbazine alone or
combined with aerosol CpG-ODN/Poly(I:C) (four mice/group)
were digested in DMEM medium containing collagenase
(300 U/mL) and hyaluronidase (100 U/mL) (Stemcell Technol-
ogies, 07912) for 1 hr at 37C. Lungs of untreated mice injected
with tumor cells were used as control. Cell suspensions were fil-
tered through 70-mm cell strainers and, after lysis of red blood
cells, stained for 30 min at 4C with the following directly conju-
gated antibodies: CD45APCeFluor780 (eBioscience, clone 30-
F11); CD3ePE (Miltenyi, clone 145-2C11); CD49bFITC (Mil-
tenyi, clone DX5); CD69APC (Miltenyi, clone H1.2F3);
CD314PeVio770 (NKG2D, Miltenyi, clone CX5),CD11bPE
(BD, M1/70); CD11cPE-Cy7 (eBioscience, N418); F4/
80PerCPCy5.5 (eBioscience, BM8). Purified rat anti-mouse
CD16/CD32 monoclonal (eBiosciences, clone 93) was used to
prevent nonspecific binding to mouse Fc receptors. Cells were
examined using a FACSCanto flow cytometer (BD Biosciences)
and data were analyzed using FlowJo software (TreeStar). All
analyses were performed gating on CD45C cells that fell within
the lymphocyte population (FSClowSSClow) after doublet
exclusion to detect NK cell infiltrate. To detect expression of
NKG2D ligands, B16 melanoma cells cultured for 24 hr in com-
plete medium supplemented or not with different concentrations
of dacarbazine (0.2, 0.4, 0.6, 0.8, 1.0, 1.2 g/L) were washed,
stained for 30 min at 4C with RAE1gammaPE (eBioscience,
clone CX1) or MULT1PE (eBioscience, clone 5D10) or Isotype
control (eBioscience, 14-4031 and 14-4888) and analyzed by
FACScanto as above.
In vitro NK degranulation and cytotoxic assays
To evaluate NK cell degranulation, CD107a mobilization was
assayed. Briefly, lungs from mice injected with tumor cells and
treated for 2 weeks with aerosolized CpG-ODN/Poly(I:C) or
with dacarbazine alone or combined with aerosol CpG-ODN/
Poly(I:C) (4 mice/group) or left untreated were digested in
DMEM medium containing collagenase (300 U/mL) and
hyaluronidase (100 U/mL) for 1 hr at 37C and lung suspen-
sions were restimulated in vitro by co-culture with B16 mela-
noma cells. After 24 hr, non-adherent cells were collected and
incubated in FACS tubes with B16 tumor cells (60:1) and
CD107a-APC LAMP1 antibody (Miltenyi, clone 1D4B) for 1
hr at 37C. Monensin (eBiosciences, 00-4505-51) was added to
a final concentration of 6 mg/mL and cells were incubated for an
additional 3 hr at 37C. Fifteen minutes before the end of the
incubation, cells were stained with CD3FITC (Miltenyi, clone
17A2), CD49PE (Miltenyi, clone DX5) and CD45APCe-
Fluor780 (eBiosciences, clone 30-F11) antibodies. After washing,
cells were resuspended in FACS Buffer, 7AAD (BD, 555816)
was added to each tube and cells were analyzed by flow cytometry
as described above. For in vitro cytotoxicity assay, lung suspen-
sions were plated in 24 wells plate for 2 hr at 37C; non-adherent
cells were then recovered and co-cultured in 96 wells U-bottom
plate for 12 hr with 2£104 B16 tumor cells (5:1) labeled with
CFSE (Life Technologies C1157) according to manufactured
protocol. After incubation, cells were harvested, 7AAD was
added to each sample and cytotoxicity evaluated by flow cytome-
try assessing the percentage of CFSEC 7AADC cells.
Statistical analysis
PCR data were analyzed by the DDCt method. Differences in
the different groups in all experiments were compared using two-
tailed unpaired Student’s t-test.
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